Skip to main content
. 2018 Apr 17;9(29):20426–20438. doi: 10.18632/oncotarget.24921

Table 3. KRAS exon 2 mutations in CD166 positive and CD166 negative CRC.

CRC c.35G>A (G12D) c.35G>T (G12V) c.34G>A (G12S) Total
CD166 positive 18/49 (37%) 8/49 (16%) 3/49 (6%) 29
CD166 negative 5/21 (24%) 2/21 (10%) 0/21 (0.0%) 7
Total 23 10 3 36